Stocktoria

Rallybio Corp RLYB

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-07-29 · LEI

Rallybio Corp statistics & valuation

Market cap$84.8M
P / S98.8×
P / B1.5×
Net margin-1046.4%
Return on equity-15.5%
Return on capital-57%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-9084.10% -1046.40% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-9511.90% -3853.60% 202020212022202320242025
Return on equity (%)
-19.40% -26.80% -39.40% -70.20% -93.70% -15.50% 202020212022202320242025
Shares outstanding
23.4M 32.1M 37.8M 40.4M 5.4M 5.6M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-18.60% -25.80% -36.90% -64.50% -84.80% -14.40% 202020212022202320242025
Free cash flow margin (%)
-7748.70% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$1.84 -$2.09 -$1.84 -$10.61 -$1.59 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-3853.6%-9511.9%————
Net margin-1046.4%-9084.1%————
FCF margin—-7748.7%————
Return on assets-14.4%-84.8%-64.5%-36.9%-25.8%-18.6%
Return on equity-15.5%-93.7%-70.2%-39.4%-26.8%-19.4%
Current ratio14.5010.8712.3916.7127.6124.18

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.